Peptides.info

Long-acting amylin analog

Cagrilintide

Clinical

Also known as NN9838, CagriSema (with semaglutide)

The amylin half of the next weight-loss combination.

Cited sources
2
Human-tested claims
2 of 2
Best evidence
Tier 2 · Clinical
Status
Research-only

A once-weekly, lipidated analog of amylin, the pancreatic satiety hormone. Alone it produced weight loss comparable to liraglutide in Phase 2; paired with semaglutide as CagriSema it reached the low twenties in Phase 3. It is not approved in any form.

metabolicamylininvestigational

How it works

Amylin is co-released with insulin and signals fullness through the brainstem, slowing gastric emptying and suppressing glucagon. Cagrilintide is a stabilized, fatty-acid-linked version built to last a week. Its appeal is additivity: amylin and GLP-1 act on different receptors, so the combination can outdo either alone.

Sequence: 37-residue amylin analog with stabilizing substitutions and a C20 fatty-diacid side chainDescribed rather than spelled out: the exact substitutions are in the sponsor's chemistry papers and have not been letter-verified here.

What it's studied for

One claim per card, each with its own tier and source. Tiers 1 and 2 are human data. Tiers 3 and 4 are not yet.

Safety & limitations

Gastrointestinal events, mainly nausea, were more common than placebo at every dose in Phase 2, along with injection-site reactions; discontinuation rates were similar across groups.

[1]Lau et al., 2021 (Lancet, Phase 2)(opens in a new tab)

In the Phase 3 combination trial, gastrointestinal adverse events affected about four in five participants on CagriSema versus two in five on placebo, mostly transient and mild to moderate.

[2]Garvey et al., 2025 (NEJM, REDEFINE 1)(opens in a new tab)

Regulatory & legal status

Research-only

Investigational. Neither cagrilintide alone nor the CagriSema combination is approved anywhere as of this review; Phase 3 results for the combination were published in 2025.

[2]Garvey et al., 2025 (NEJM, REDEFINE 1)(opens in a new tab)

Frequently asked

Is cagrilintide a GLP-1 drug?

No. It mimics amylin, a different hormone with a different receptor. That is exactly why it is being paired with semaglutide: the two signals add rather than overlap.

How much does cagrilintide add to semaglutide?

In REDEFINE 1 the combination produced about 20% weight loss at 68 weeks against 3% on placebo. The trial also ran each drug alone, and the combination beat both arms.

References

  1. [1]Lau et al., 2021 (Lancet, Phase 2) (opens in a new tab)
  2. [2]Garvey et al., 2025 (NEJM, REDEFINE 1) (opens in a new tab)

Written by Twenty Residues editorial. Medical review: pending; a named reviewer is being assigned.

Last updated October 1, 2026.

Spot an error or a better source? Report a correction. Every change is logged below.

Update history
  • 2026-10-01 — Entry added.